WEST CONSHOHOCKEN, Pa., April 20 /PRNewswire-FirstCall/ -- Dermisonics, Inc. (BULLETIN BOARD: DMSI) announced today that it has formed a Business Advisory Council to guide and advise the Company. Dermisonics is a medical device company with its focus on the development and commercialization of an ultrasonically assisted, transdermal drug-delivery technology, the U-Strip(TM). The purpose of the Advisory Council is to assist the Company in formulating optimal strategies to generate strategic alliances within the pharmaceutical industry, access capital to continue and extend the research and development of its technology, and to assist the Company with matters of corporate governance, fiscal management, capital formation, and marketing and licensing issues.
Initially, the Advisory Council will consist of three members: Gary Scott, Dr. Georg Hochwimmer, and Adil Saleh, each with a distinct background and skill set. Mr. Scott will chair the Advisory Council.
Gary Scott is an international business and sales management leader specializing in information technology. He has built the foundations of the European subsidiaries of major American companies. He currently serves as Chairman and lead investor in Office Canopy Group, an e-commerce solutions company, where his role is strategic, financial, and managerial. Previously, he served as a high-ranking corporate officer of StorageWay, Inc., a provider of storage utility services, and MTI Technology Corporation, a data storage solutions company where Mr. Scott established and rapidly expanded the company’s European presence. Mr. Scott’s strengths lie in his ability to provide an enterprise with direction and strategic planning in its growth trajectory.
Dr. Hochwimmer is chief analyst at General Research, GmbH, a leading Munich-based securities research and analysis firm. Dr. Georg Hochwimmer is a noted business consultant and academic responsible for aiding in the development of several highly profitable companies throughout Europe. He has served on the Board of Directors of Maxxio Technologies AG, Lokando AG, and Prevero AG. He is Managing Director of Bluespectrum GmbH, and he previously served as Managing Director of General Research GmbH. Published in international scientific publications, Dr. Hochwimmer has earned advanced degrees in chemistry, machinery engineering, computer science, and polymer chemistry.
Adil Saleh currently serves as President of Pharmacy Fulfillment Direct, the sole provider of pharmacy services to TheCanadianDrugstore.com, Canada’s fourth largest online pharmaceutical retailer. Formerly, he served as interim CEO of Kortrack Solutions, a company that develops software solutions for pharmaceutical giants such as Eli Lilly. Mr. Saleh is a pharmaceutical studies graduate of the University of Alberta, as well as an international healthcare educator to professionals in the field and guest lecturer for the University of British Columbia Faculty of Medicine.
Bruce Haglund, Chairman and interim CEO of Dermisonics commented, “We have chosen these three individuals to serve on our Advisory Council precisely because of their wide-ranging skills and ability to assist the Company in various ways. We hope to leverage their extensive experience to our advantage in a number of areas to allow our enterprise to advance more rapidly toward its objectives.”
About Dermisonics, Inc.
Dermisonics Inc. is a medical device company that is focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of heavy molecular drugs into the system. The U-Strip(TM) is a drug delivery system incorporating a transdermal patch in combination with microelectronics and ultrasonic technology. Preliminary tests have shown that this system facilitates the transdermal delivery of insulin as well as numerous other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size.
For further information contact Bruce Haglund at 949-733-1101 or by e-mail at bruce.haglund@dermisonics.com.
Dermisonics, Inc. Four Tower Bridge 200 Bar-Harbor Drive West Conshohocken, Pa. 19428-2977 USA Toll Free: 888-401-DERM (3376) Phone: 610-941-2780 Fax: 610-941-2990 North American Investor Relations Contact: John Robinson Phone: 866-559-1333 johnrobinson@currentcapital.com European Investor Relations Contact: Alexander Holterman Phone: +49-69-6062-7858 ir-germany@dermisonics.com For additional information, please visit http://www.dermisonics.com/ Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward- looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company’s products, technical problems with the Company’s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.
Contact: North American Investor Relations, John Robinson, +1-866-559-1333, or johnrobinson@currentcapital.com, for Dermisonics; or European Investor Relations, Alexander Holterman of Dermisonics, +49-69-6062-7858, or ir-germany@dermisonics.com.
Dermisonics, Inc.
CONTACT: North American Investor Relations, John Robinson,+1-866-559-1333, or johnrobinson@currentcapital.com, for Dermisonics; orEuropean Investor Relations, Alexander Holterman of Dermisonics,+49-69-6062-7858, or ir-germany@dermisonics.com
Web site: http://www.dermisonics.com/
